Benutzer: Gast  Login
Titel:

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't; Review
Autor(en):
Pradhan, Aruna D; Paynter, Nina P; Everett, Brendan M; Glynn, Robert J; Amarenco, Pierre; Elam, Marshall; Ginsberg, Henry; Hiatt, William R; Ishibashi, Shun; Koenig, Wolfgang; Nordestgaard, Børge G; Fruchart, Jean-Charles; Libby, Peter; Ridker, Paul M
Abstract:
Observational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α), pemafibrate, will be used to target residual cardiovascular risk remaining after treatment to reduce low-density lipoprotein cholesterol (LDL-C)...     »
Zeitschriftentitel:
Am Heart J
Jahr:
2018
Band / Volume:
206
Seitenangaben Beitrag:
80-93
Volltext / DOI:
doi:10.1016/j.ahj.2018.09.011
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/30342298
Print-ISSN:
0002-8703
TUM Einrichtung:
Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert)
 BibTeX